Ann: MOU with Temasek-linked Innoventures - Orthopaedics in China, page-30

Yes Migy119 - it will or might get way worst before they get better revenues.

This is the hard reality points:

- we are in a risk averse period,
- Biotechs are high risk segments to begin with,
- Revenue is key to any company, let alone OSX - they are below par at this stage, so they have a very low fair value
- They have low to no cash, further dilution is possible. Investors know this.

Until they show revenue growth, all their prospects are fluff talk. It might work out - but we have to wait for a few years and track them.